Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9
OTLK•CFO buys shares and warrants in public offering
Outlook Therapeutics CFO Lawrence A. Kenyon bought 101,010 common shares in an underwritten public offering priced at $0.99 per share.
Kenyon’s direct ownership rose to 106,956 shares following the purchase.
He also bought 101,010 warrants exercisable at $1.1, expiring Aug. 14, 2031.
